<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00256139</url>
  </required_header>
  <id_info>
    <org_study_id>24011</org_study_id>
    <nct_id>NCT00256139</nct_id>
  </id_info>
  <brief_title>CLEAR Study: Clinical Experience Acquired With Raptiva Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <brief_summary>
    <textblock>
      A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously&#xD;
      administered Raptiva in the treatment of patients with moderate to severe psoriasis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Actual">793</enrollment>
  <condition>Moderate to Severe Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raptiva</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Plaque psoriasis covering ³10% of total BSA (see Appendix A)&#xD;
&#xD;
          -  Diagnosis of psoriasis for at least 6 months&#xD;
&#xD;
          -  A minimum PASI score of 12.0 at screening (see Appendix A)&#xD;
&#xD;
          -  Patients who are either not controlled by, intolerant to or contraindicated to at&#xD;
             least 2 currently available systemic therapies (e.g., photochemotherapy (PUVA),&#xD;
             cyclosporin, corticosteroids, methotrexate, oral retinoids, MMF, thioguanine,&#xD;
             hydroxyurea, sirolimus, azathioprine, 6 MP) (defined as &quot;high need&quot; patients)&#xD;
&#xD;
          -  Body weight &lt;= £120 kg&#xD;
&#xD;
          -  18 to 75 years old&#xD;
&#xD;
          -  For women of childbearing potential, use of an acceptable method of contraception to&#xD;
             prevent pregnancy and agreement to continue to practice an acceptable method of&#xD;
             contraception for the duration of their participation in the study&#xD;
&#xD;
          -  Willingness to hold sun exposure reasonably constant and to avoid use of tanning&#xD;
             booths or other UV light sources during the study&#xD;
&#xD;
          -  Willingness to enter Study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to humanised monoclonal&#xD;
             antibodies or fusion proteins that contain an Ig Fc region&#xD;
&#xD;
          -  Clinically significant psoriasis flare during screening or at the time of enrollment&#xD;
&#xD;
          -  History of or ongoing uncontrolled bacterial, viral, fungal, or atypical mycobacterial&#xD;
             infection&#xD;
&#xD;
          -  History of opportunistic infections (e.g., systemic fungal infections, parasites)&#xD;
&#xD;
          -  Seropositivity for human immunodeficiency virus (HIV) Patients will undergo mandatory&#xD;
             testing at screening. Patients who are positive for HIV will be excluded.&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  WBC count &lt;4000/mL or &gt;14,000/mL&#xD;
&#xD;
          -  Seropositivity for hepatitis B or C virus Patients will undergo testing during&#xD;
             screening. Patients who are positive for hepatitis B antigen or hepatitis C antibody&#xD;
             will be excluded.&#xD;
&#xD;
          -  Hepatic enzymes ³3 times the upper limit of normal&#xD;
&#xD;
          -  History of active tuberculosis (TB) or currently undergoing treatment for TB PPD&#xD;
             testing or chest X-ray is required for high risk patients (see Appendix I). Patients&#xD;
             with a positive PPD (not due to BCG vaccination) or chest X-ray will be excluded.&#xD;
&#xD;
          -  Presence of malignancy within the past 5 years, including lymphoproliferative&#xD;
             disorders Patients with a history of fully resolved basal cell or squamous cell skin&#xD;
             cancer may be enrolled.&#xD;
&#xD;
          -  Previous treatment with Raptiva (anti-CD11a)&#xD;
&#xD;
          -  Diagnosis of hepatic cirrhosis, regardless of cause or severity&#xD;
&#xD;
          -  Serum creatinine ³2 times the upper limit of normal&#xD;
&#xD;
          -  Hospital admission for cardiac disease, stroke, or pulmonary disease within the last&#xD;
             year&#xD;
&#xD;
          -  History of substance abuse within the last 5 years&#xD;
&#xD;
          -  Any medical condition that, in the judgment of the investigator, would jeopardize the&#xD;
             patient's safety following exposure to study drug&#xD;
&#xD;
        Note: Restrictions and/or directions apply to the following treatments during specified&#xD;
        time periods prior to initial study drug administration and during the study:&#xD;
&#xD;
          -  Systemic therapy for psoriasis (within 28 days prior to Study Day 0)&#xD;
&#xD;
          -  Systemic immunosuppressive drugs for other indications (within 28 days prior to Study&#xD;
             Day 0)&#xD;
&#xD;
          -  Topical therapies for psoriasis (within 14 days prior to Study Day 0)&#xD;
&#xD;
          -  Live or killed virus or bacteria vaccines (within 14 days prior to Study Day 0)&#xD;
&#xD;
          -  Other vaccines or allergy desensitisation (it is recommended that these are scheduled&#xD;
             at least 14 days prior to Day 0 or ³3 months after the last injection of study drug)&#xD;
&#xD;
          -  Other experimental drugs or treatments (within 28 days or five half lives, whichever&#xD;
             is longer, prior to Day 0) b Blockers, ACE inhibitors, interferons, quinidine,&#xD;
             antimalarial drugs, or lithium (if clinically indicated, such medications are allowed&#xD;
             but the dosage should be held constant from Day -28 throughout the study)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Patrick Natta, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Serono International SA</name>
      <address>
        <city>Geneva</city>
        <zip>1202</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.biomedcentral.com/1471-5945/5/13</url>
    <description>CLEAR trial</description>
  </link>
  <results_reference>
    <citation>Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, Shear NH, Papp KA; CLEAR Multinational Study Group. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol. 2006 Jul;155(1):170-81.</citation>
    <PMID>16792770</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>November 18, 2005</study_first_submitted>
  <study_first_submitted_qc>November 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <last_update_submitted>January 13, 2017</last_update_submitted>
  <last_update_submitted_qc>January 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2017</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

